PROTACs
Financiado
Design synthesis and biological evaluation of PROteolysis TArgeting Chimeric P...
Design synthesis and biological evaluation of PROteolysis TArgeting Chimeric PROTAC molecules as anticancer agents
Cancer diseases are critical medical problems - according to the International Agency for Research on Cancer and European Commission estimates, globally there were more than 18 million new cases and 9.5 million cancer-related deat...
Cancer diseases are critical medical problems - according to the International Agency for Research on Cancer and European Commission estimates, globally there were more than 18 million new cases and 9.5 million cancer-related deaths in 2018, what indicates that tumors are among the leading causes of death, worldwide.
Traditional anticancer drug design based on small molecules continues to be a powerful strategy for the development of novel chemotherapeutics. However, these anticancer therapies are facing major problems such as drug resistance, especially in advanced cancers. This is mainly due to the alterations in the target, ineffective apoptosis or activation of different pathways, among others. The use of PROteolysis-TArgeting Chimerics (PROTACs) has become a promising approach to overcome resistance since they act degrading instead of inhibiting the target, with the advantage of reducing the systemic drug exposure and to counteract the protein expression that often accompanies inhibition of protein function. This approach uses bivalent molecules that possess a target protein recruiting group linked to an E3 ligase interacting moiety for protein degradation.
The main goal of this project is to design, synthesize and evaluate a series of new small-molecule PROTACs, which will be able to degrade enzymes and receptors that are responsible for tumor development and progression. To address this aim, I shall carry out a fellowship at Universidad San Pablo CEU under the supervision of Prof. Beatriz de Pascual-Teresa and Irene Ortín from Faculty of Pharmacy. As part of this research, I shall carry out a secondment in the Department of Molecular Biotechnology and Health Sciences at University of Turin (Italy), and another one at the company CsFlowChem S.L. It is worth noting that the design and synthesis of new PROTACs will be based on our wide experience in the development of compounds responsible for inhibition or regulation of the selected target proteins.
ver más
Duración del proyecto: 35 meses
Fecha Inicio: 2021-04-23
Fecha Fin: 2024-04-03
Fecha Fin: 2024-04-03
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2024-04-03
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
MSCA-IF-2020:
Individual Fellowships
Cerrada
hace 4 años
Presupuesto
El presupuesto total del proyecto asciende a
173K€
Líder del proyecto
FUNDACION UNIVERSITARIA SAN PABLO CEU
No se ha especificado una descripción o un objeto social para esta compañía.
Total investigadores
20
Total investigadores
20